» Articles » PMID: 18300338

Role of Symptoms in Diagnosis and Outcome of Gastric Cancer

Overview
Specialty Gastroenterology
Date 2008 Feb 27
PMID 18300338
Citations 97
Authors
Affiliations
Soon will be listed here.
Abstract

Gastric cancer is one of the most common cancers and the second most common cause of cancer deaths worldwide. Apart from Japan, where screening programmes have resulted in early diagnosis in asymptomatic patients, in most countries the diagnosis of gastric cancers is invariably made on account on dyspeptic and alarm symptoms, which may also be of prognostic significance when reported by the patient at diagnosis. However, their use as selection criteria for endoscopy seems to be inconsistent since alarm symptoms are not sufficiently sensitive to detect malignancies. In fact, the overall prevalence of these symptoms in dyspeptic patients is high, while the prevalence of gastro-intestinal cancer is very low. Moreover, symptoms of early stage cancer may be indistinguishable from those of benign dyspepsia, while the presence of alarm symptoms may imply an advanced and often inoperable disease. The features of dyspeptic and alarm symptoms may reflect the pathology of the tumour and be of prognostic value in suggesting site, stage and aggressiveness of cancer. Alarm symptoms in gastric cancer are independently related to survival and an increased number, as well as specific alarm symptoms, are closely correlated to the risk of death. Dysphagia, weight loss and a palpable abdominal mass appear to be major independent prognostic factors in gastric cancer, while gastro-intestinal bleeding, vomiting and also duration of symptoms, do not seem to have a relevant prognostic impact on survival in gastric cancer.

Citing Articles

Saliva as a Diagnostic Tool for Systemic Diseases-A Narrative Review.

Surdu A, Foia L, Luchian I, Trifan D, Tatarciuc M, Scutariu M Medicina (Kaunas). 2025; 61(2).

PMID: 40005360 PMC: 11857487. DOI: 10.3390/medicina61020243.


Metformin reverses 5-FU chemoresistance by downregulating DKK1, WNT5A, and ABCB1 expressions in gastric cancer: An experimental and bioinformatic study.

Asghariazar V, Vakili Ojarood M, Vatankhah M, Panahizadeh R, Haris H, Najafzadeh N Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39954066 DOI: 10.1007/s00210-025-03879-5.


Immunotherapy in gastric cancer-A systematic review.

Santos M, Martins D, Mendes F Oncol Res. 2025; 33(2):263-281.

PMID: 39866237 PMC: 11753986. DOI: 10.32604/or.2024.052207.


Relationship between [F]FDG PET/CT findings and claudin 18.2 expression in metastatic gastric cancer.

Yin H, Luo R, Lv J, Mao W, Shi H Eur Radiol. 2024; .

PMID: 39572448 DOI: 10.1007/s00330-024-11186-5.


Metastatic bone lesion type in gastric cancer patients: imaging findings of case reports.

Porta-Vilaro M, Soler-Perromat J, Larque A, Bartolome-Solanas A, Isern-Kebschull J, Garcia-Diez A Quant Imaging Med Surg. 2024; 14(11):7872-7880.

PMID: 39544462 PMC: 11558497. DOI: 10.21037/qims-24-425.


References
1.
Everett S, Axon A . Early gastric cancer in Europe. Gut. 1997; 41(2):142-50. PMC: 1891459. DOI: 10.1136/gut.41.2.142. View

2.
Fernandez E, Porta M, Malats N, Belloc J, Gallen M . Symptom-to-diagnosis interval and survival in cancers of the digestive tract. Dig Dis Sci. 2002; 47(11):2434-40. DOI: 10.1023/a:1020535304670. View

3.
DeWys W, Begg C, Lavin P, Band P, Bennett J, Bertino J . Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980; 69(4):491-7. DOI: 10.1016/s0149-2918(05)80001-3. View

4.
Haugstvedt T, Viste A, Eide G, Soreide O . Factors related to and consequences of weight loss in patients with stomach cancer. The Norwegian Multicenter experience. Norwegian Stomach Cancer Trial. Cancer. 1991; 67(3):722-9. DOI: 10.1002/1097-0142(19910201)67:3<722::aid-cncr2820670332>3.0.co;2-r. View

5.
Manes G, Balzano A, Marone P, Lioniello M, Mosca S . Appropriateness and diagnostic yield of upper gastrointestinal endoscopy in an open-access endoscopy system: a prospective observational study based on the Maastricht guidelines. Aliment Pharmacol Ther. 2002; 16(1):105-10. DOI: 10.1046/j.1365-2036.2002.01136.x. View